Vera set up for full approval for Trutakna in IgAN with Phase III win

Vera’s Trutakna was granted FDA accelerated approval in IgAN based on 36-week data. Vera’s Trutakna was granted FDA accelerated approval in IgAN based on 36-week data. IgAN, also known as Berger’s disease, is a chronic kidney condition that develops when immunoglobulin A builds up in the small filtering units of the kidneys. Credit: sasirin pamai / Shutterstock.com Vera Therapeutics looks well placed for full approval of Trutakna (atacicept-vymj) in primary IgA nephropathy (IgAN) after successful confirmatory data. In the Phase III ORIGIN 3 trial (NCT04716231), patients treated with Trutakna saw a 0.1mL/min/1.73m2 reduction in mean estimated glomerular filtration rate (eGFR)…

Source: Clinical Trials Arena